pharmaphorum

DECEMBER 2, 2022

Read on for key stories from this year’s Frontiers Health conference in Italy, unlocking the promise of patient support programmes in oncology, supercharging communications with modular content, and much more. Unlocking the promise of patient support programmes in oncology. Read Deep Dive: Digital Health 2022 in full.

Communication 52

Communication Vaccines Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

SEPTEMBER 22, 2022

Read on to find out about unlocking the potential of connected commercialisation solutions, what HCPs want from post-pandemic communication, achieving launch excellence in oncology and much more. Achieving launch excellence in oncology. A successful launch in the oncology space is not guaranteed; it is strategically planned and earned.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

AUGUST 18, 2022

Last month in Chicago, Illinois the American Society of Clinical Oncology hosted its first in-person meeting since the COVID-19 pandemic began. Led by Merck’s blockbuster Keytruda, these drugs have been making waves in the oncology space for some time, and this year’s ASCO kept up that trend.

Chemotherapy 52

Chemotherapy Immunity Immunization 52

pharmaphorum

JULY 12, 2021

The pandemic forced massive changes to oncology sites to ensure patient safety and research continuity – but we must recalibrate and work with sites to understand the value proposition of the technologies and methodologies adopted, says Syneos Health’s Angela Hirst.

52

52

pharmaphorum

APRIL 30, 2021

Blogger Chris Aldred and Joe Delahunty from Ascensia discuss what the industry often gets wrong in its patient engagement. • Read the latest issue Deep Dive: Market Access 2021 in full. Subscribe to future issues of Deep Dive. The post Deep Dive: Market Access appeared first on.

Communication 98

Communication Pharmaceutical Companies Pharmaceutical Companies Vaccines 98

pharmaphorum

OCTOBER 6, 2022

Many of these challenges are exacerbated in oncology, where the treatment landscape rapidly evolves with novel mechanisms of actions (e.g., Strategic planning and early investments in HCP and patient education are critical success factors for small and emerging companies launching oncology products.

Communication 52

Communication 52

pharmaphorum

MAY 6, 2022

Combination pricing: access to the future of oncology treatment. Read Deep Dive: Market Access in full. pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique research for pharmaceutical companies, biotech firms and the wider healthcare sector.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

AUGUST 4, 2022

Over the past two decades, innovative research efforts, such as the Human Genome Project and 100,000 Genomes Project, have vastly expanded our understanding of the human genome and its role in driving research and development in oncology. The post Realising the promise of genomic testing across oncology appeared first on.

52

52

pharmaphorum

JULY 23, 2021

If ASCO 2021 proves anything, it’s that the explosion in immuno-oncology therapies over the last few years shows no signs of slowing down. The post Digital tools key to immuno-oncology’s future: report appeared first on. As the field becomes more crowded, digital tools may be critical for improving outcomes, says a new whitepaper.

52

52

pharmaphorum

DECEMBER 14, 2020

As this issue’s title suggests, patient centricity is about more than just talking points and marketing strategies – it requires companies to truly listen to, engage with and partner with the patients they serve, and in putting this month’s Deep Dive together it’s been great to see that so many pharma firms are now taking this to heart.

Pharmaceutical Companies 76

Pharmaceutical Companies Pharmaceutical Companies 76

pharmaphorum

JULY 21, 2021

COVID’s impact on cancer care and oncology research has been devastating, but the pandemic has also opened up opportunities to take learnings and create long-lasting change in research, practice and education, says Lucid’s Frances O’Connor. The post Oncology and a year of COVID: lessons for the future appeared first on.

52

52

pharmaphorum

DECEMBER 14, 2022

Fuelled by technological advancements, patient support programmes (PSPs) – also known as patient assistant programmes – are gaining attention as a potential way to deliver continual care for oncology patients. The post Unlocking the promise of patient support programmes in oncology appeared first on.

52

52

pharmaphorum

SEPTEMBER 17, 2020

Patient simulations have been a key tool for educating physicians for decades – and now cutting-edge tech is helping them become more impactful than ever. • Read the latest issue Deep Dive: Communications 2020 in full. Subscribe to future issues of Deep Dive. The post Deep Dive: Communications 2020 appeared first on.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JANUARY 18, 2022

With so many active research areas in oncology, patients and their loved ones can easily be overwhelmed by information and not know where to direct their attention. As Rebecca Goldstein says, “The fact is we have a lot of really active drugs in cancer right now. The post Targeted agents and immunotherapies appeared first on.

98

98

pharmaphorum

JUNE 7, 2022

But the issue around pricing and reimbursement of combination therapies within the current healthcare system isn’t something I – or the pharmaceutical industry – can resolve in isolation. • Read the full article in pharmaphorum’s Deep Dive digital magazine.

52

52

pharmaphorum

JULY 19, 2021

“Because of that, companies are under a lot of pressure to get a return on investment from these meetings.”. • Read the full article in pharmaphorum’s Deep Dive digital magazine. The post How hybrid virtual engagement is accelerating oncology communication appeared first on.

Communication 52

Communication 52

pharmaphorum

FEBRUARY 26, 2021

From animal processing, to cell therapy and AI, Tim Mullane, president, and chief operating officer tells pharmaphorum how FUJIFILM Irvine Scientific has evolved to become one of the top manufacturers of cell culture media. • Read the latest issue Deep Dive: Research and Development 2021 in full.

Vaccines 59

Vaccines Communication Pharmaceutical Companies Pharmaceutical Companies 59

pharmaphorum

JULY 28, 2021

“As research in the area has grown, we do see more discussions and participate with various organizations on the work around defining standards – but there are still gaps.”. • Read the full article in pharmaphorum’s Deep Dive digital magazine.

52

52

pharmaphorum

NOVEMBER 2, 2020

Most of the digital health experts we spoke to for this issue of Deep Dive made one thing clear – no one can really say what the future holds for digital tech in the pharma and healthcare industries. Subscribe to future issues of Deep Dive. The post Deep Dive: Digital Health Innovation 2020 appeared first on.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies 59

pharmaphorum

JULY 26, 2021

Imagine you are a pharma executive working in oncology R&D. Evidence shows that, despite historical success, the oncology R&D pipeline is unsustainable, not only becoming increasingly difficult and costly, but also fast approaching relative stagnation. The landscape is rapidly becoming more competitive and overcrowded.

Drug Pricing 52

Drug Pricing Drug Development 52

pharmaphorum

MARCH 21, 2022

Designed for experts working directly on myeloid-directed therapies, and those in adjacent immuno-oncology fields, from cell therapy to checkpoint and engager development.

52

52

pharmaphorum

APRIL 20, 2021

Join global investors to: Leverage the knowledge gained from the current EGFR-TKI successes to implement it into strategies for improvement, best application strategies and potential combination partners with AstraZeneca, Puma Biotechnology, Cullinan Oncology and Takeda. View the event guide now for more details!

Drug Development 52

Drug Development Medical Schools Immunity Immunization 52

pharmaphorum

NOVEMBER 22, 2021

Celebrating 20 years of FDA approval and high efficacy profiles, kinase inhibitors have changed the face of oncology treatment. Turbocharge the Development of the Best-In-Class Kinase Inhibitor Products, to Enhance Specificity, Overcome Resistance to Deliver Safe & Durable Clinical Responses.

Medical Schools 52

Medical Schools Drug Development 52

pharmaphorum

JUNE 8, 2021

Speaking to us after his appearance on the Withers podcast Talking Success , Mei says he founded Antengene – after leading oncology drug development at J&J, Novartis and Celgene– to address this need for innovative drugs with best-in-class and/or first-in-class potential targeting medical needs specific to APAC. Unmet needs in cancer.

Chemotherapy 105

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunity 105

pharmaphorum

MAY 10, 2021

This article appears in full in this month’s Deep Dive digital magazine on Market Access. More granular data from the US demonstrates a wide variation across specialities, with oncology particularly lagging behind in total promotional activity.

Hospitals 90

Hospitals 90

Express Pharma

APRIL 4, 2024

Deep dive into differences: Liposomes vs. LNPs Morphology: In technical terms, LNPs encompass nanoparticles incorporating lipids, with liposomes falling under this category. Within the scientific literature, the term LNP specifically denotes a distinct particle type differing from liposomes in morphology, size, and composition.

Vaccines 79

Vaccines Compounding Immunity Immunization 79

pharmaphorum

JULY 14, 2021

“The next frontier is really around digital solutions that cause drug-like changes in the body; so far, these are typically seen in CNS – the video game Akili for ADHD being one example.”. • Read the full article in pharmaphorum’s Deep Dive digital magazine.

59

59

pharmaphorum

AUGUST 2, 2021

“They’re missing the buzz of having the institute full, and the resulting creative interaction that can spark new ideas.”. • Read the full article in pharmaphorum’s Deep Dive digital magazine. The post Cancer research faces uncertain post-COVID landscape appeared first on.

52

52

pharmaphorum

JULY 30, 2021

How wrong we were. • Read the full article in pharmaphorum’s Deep Dive digital magazine. Past experience led most of us to place an optimistic scenario at 12 months, but more realistically 18 months. The post Surprise pandemic lessons for pharma appeared first on.

Vaccines 52

Vaccines 52

pharmaphorum

JULY 16, 2021

Although a start-up’s long-term vision will always come from the entrepreneurs behind it, the challenges that founders face can come thick and fast as they navigate both financing options and operating risk. • Read the full article in pharmaphorum’s Deep Dive digital magazine.

40

40

pharmaphorum

APRIL 26, 2021

Neurology is particularly slow in digital adoption, partly because it is not as well understood as diseases like oncology and diabetes, and there are fewer standards against which to validate technologies,” she says. George Underwood is the editor for pharmaphorum’s Deep Dive digital magazine. About the author.

Diabetes 105

Diabetes 105

pharmaphorum

MAY 18, 2022

“Data is becoming an essential element in early decision making around clinical trials both in terms of the countries that are selected to take part but also sites that take part,” explained Roche’s therapy relationship manager, oncology, Ed Merivale. “It Ed Merivale is therapy relationship manager, oncology at Roche. moderator).

Diabetes 81

Diabetes Hospitals 81

pharmaphorum

DECEMBER 14, 2022

To complement virtual connections, the team meets every two months at the Casa Angelini headquarters in Rome for intense one-week deep dives, brainstorming sessions, and team bonding activities. “We He is on the board of Genialis, an AI drug discovery company, and a venture partner at First Star Ventures, a Boston-based deep tech fund.

Drug Development 105

Drug Development 105

PharmaShots

JUNE 28, 2023

Before we deep dive into its sales analysis of each year, let us first look at how this product was launched and its related collaborations. and Canada for all approved indications other than oncology. and Canada for oncology indications were reserved for Amgen. The rights to promote Enbrel in the U.S.

Biosimilars 40

Biosimilars Insurance Coverage and Processing Dosage Compounding 40

pharmaphorum

JULY 9, 2021

The company has also expanded the platform into similar inflammatory conditions in rheumatology, dermatology and oncology. You can read this article and other articles on digital health in the latest issue of pharmaphorum’s Deep Dive digital magazine. About the interviewees.

Hospitals 69

Hospitals Communication Immunity Immunization 69